参考文献/References:
[1] Chatterjee S,Biondi-Zoccai G,Abbate A,et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction:network meta-analysis[J]. BMJ,2013,346:f55.
[2] Cleland JGF,Bunting KV,Flather MD,et al. Beta-blockers for heart failure with reduced,mid-range,and preserved ejection fraction:an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J,2018,39(1):26-35.
[3] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志,2024,52(3):235-275.
[4] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e895-e1032.
[5] Arnold SV,Silverman DN,Gosch K,et al. Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction[J]. JACC Heart Fail, 2023 ,11(8 Pt 1):893-900.
[6] Wang B,Zhang L,Hu S,et al. β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction[J]. Eur Heart J Cardiovasc Pharmacother,2022,8(2):140-148.
[7] Lam PH,Gupta N,Dooley DJ,et al. Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate[J]. Am J Med,2018,131(12):1473-1481.
[8] Kaddoura R,Madurasinghe V,Chapra A,et al. Beta-blocker therapy in heart failure with preserved ejection fraction(B-HFpEF):a systematic review and meta-analysis [J]. Curr Probl Cardiol,2024,49(3):102376.
[9] Silverman DN,Plante TB,Infeld M,et al. Association of β-Blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction:a secondary analysis of the TOPCAT trial[J]. JAMA Netw Open,2019,2(12):e1916598.
[10] Tsujimoto T,Kajio H. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction[J]. Sci Rep,2018,8(1):9556.
[11] Meyer M,Du Fay Lavallaz J,Benson L,et al. Association between β-blockers and outcomes in heart failure with preserved ejection fraction:current insights from the SwedeHF registry[J]. J Card Fail,2021,27(11):1165-1174.
[12] Kotecha D,Flather MD,Altman DG,et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure[J]. J Am Coll Cardiol,2017,69(24):2885-2896.
[13] Cadrin-Tourigny J,Shohoudi A,Roy D,et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation:an AF-CHF substudy[J]. JACC Heart Fail,2017,5(2):99-106.
[14] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[15] 中华医学会心血管病学分会,中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志,2023,51(6):572-618.
[16] Dahl?f B,Sever PS,Poulter NR,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomised controlled trial[J]. Lancet,2005,366(9489):895-906.
[17] Wiysonge CS,Bradley H,Mayosi BM,et al. Beta-blockers for hypertension[J]. Cochrane Database Syst Rev,2007,1(1):CD002003.
[18] Mancia G,Kjeldsen SE,Kreutz R,et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities:indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines[J]. Hypertension,2022,79(6):1153-1166.
[19] 孙恕,易松. 2023年《中国高血压防治指南》更新临床实践[J]. 心电与循环,2023,42(3):203-206,212.
[20] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension:Endorsed by the International Society of Hypertension(ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.
[21] Weintraub WS,Spertus JA,Kolm P,et al. Effect of PCI on quality of life in patients with stable coronary disease[J]. N Engl J Med,2008,359(7):677-687.
[22] Bangalore S,Bhatt DL,Steg PG,et al. β-blockers and cardiovascular events in patients with and without myocardial infarction:post hoc analysis from the CHARISMA trial[J]. Circ Cardiovasc Qual Outcomes,2014,7(6):872-881.
[23] Bangalore S,Steg G,Deedwania P,et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease[J]. JAMA,2012,308(13):1340-1349.
[24] Godoy LC,Farkouh ME,Austin PC,et al. Association of beta-blocker therapy with cardiovascular outcomes in patients with stable ischemic heart disease[J]. J Am Coll Cardiol,2023,81(24):2299-2311.
[25] Liu L,Ding X,Chen H,et al. Associations between β-blocker therapy at discharge and long-term follow-up outcomes in patients with unstable angina pectoris[J]. Cardiol Res Pract,2022,2022:5287566.
[26] 应用β肾上腺素能受体阻滞剂规范治疗冠心病中国专家共识组. 应用β肾上腺素能受体阻滞剂规范治疗冠心病的中国专家共识[J]. 中国循环杂志,2020,35(2):108-123.
[27] Puymirat E,Riant E,Aissaoui N,et al. β blockers and mortality after myocardial infarction in patients without heart failure:multicentre prospective cohort study[J]. BMJ,2016,354:i4801.
[28] Wen XS,Luo R,Liu J,et al. Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction:a multicenter retrospective cohort study[J]. BMC Cardiovasc Disord,2022,22(1):193.
[29] Park JJ,Kim SH,Kang SH,et al. Effect of β-Blockers beyond 3 years after acute myocardial infarction[J]. J Am Heart Assoc,2018,7(5):e007567.
[30] Joo SJ,Kim SY,Choi JH,et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(6):475-482.
[31] Yndigegn T,Lindahl B,Mars K,et al. Beta-blockers after myocardial infarction and preserved ejection fraction[J]. N Engl J Med,2024,390(15):1372-1381.
[32] Bandyopadhyay D,Bajaj NS,Zein J,et al. Outcomes of β-blocker use in pulmonary arterial hypertension:a propensity-matched analysis[J]. Eur Respir J,2015,46(3):750-760.
[33] van Campen JS,de Boer K,van de Veerdonk MC,et al. Bisoprolol in idiopathic pulmonary arterial hypertension:an explorative study[J]. Eur Respir J,2016,48(3):787-796.
[34] Samaranayake CB,Kempny A,Naeije R,et al. Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension[J]. Eur Respir J,2023,61(5):2300144.
[35] 罗勤. 中国肺动脉高压诊治临床路径[J].中国循环杂志,2023,38(7):691-703.
[36] Kalay N,Basar E,Ozdogru I,et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy[J]. J Am Coll Cardiol,2006,48(11):2258-2262.
[37] Bosch X,Rovira M,Sitges M,et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies:the OVERCOME trial(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)[J]. J Am Coll Cardiol,2013,61(23):2355-2362.
[38] Gulati G,Heck SL,Ree AH,et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy(PRADA):a 2×2 factorial,randomized,placebo-controlled,double-blind clinical trial of candesartan and metoprolol[J]. Eur Heart J,2016,37(21):1671-1680.
[39] Avila MS,Ayub-Ferreira SM,de Barros Wanderley MR Jr,et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity:the CECCY trial[J]. J Am Coll Cardiol,2018,71(20):2281-2290.
[40] Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association(EHA),the European Society for Therapeutic Radiology and Oncology(ESTRO) and the International Cardio-Oncology Society(IC-OS)[J]. Eur Heart J,2022,43(41):4229-4361.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(7):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(7):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(7):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(7):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(7):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]冯颖青.β受体阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
FENG Yingqing.Role of Beta-blocker in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(7):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(7):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[11]刘思捷 蔡珍.60岁以上退行性瓣膜性心脏病合并心力衰竭的治疗研究进展[J].心血管病学进展,2024,(5):433.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.012]
LIU Sijie,CAI Zhen.Treatment of Degenerative Valvular Heart Disease Combined with Heart Failure over 60 Years of Age[J].Advances in Cardiovascular Diseases,2024,(7):433.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.012]